S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:RSLS

ReShape Lifesciences (RSLS) Stock Price, News & Analysis

$0.18
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$0.18
$0.20
50-Day Range
$0.15
$0.23
52-Week Range
$0.14
$4.10
Volume
755,418 shs
Average Volume
480,659 shs
Market Capitalization
$2.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

ReShape Lifesciences MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
4,238.4% Upside
$8.00 Price Target
Short Interest
Healthy
2.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of ReShape Lifesciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.07 out of 5 stars

RSLS stock logo

About ReShape Lifesciences Stock (NASDAQ:RSLS)

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

RSLS Stock Price History

RSLS Stock News Headlines

Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
ReShape Lifesciences Inc (RSLS)
ReShape Lifesciences, Inc.
ReShape Lifesciences Inc.
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today?
A Preview Of Reshape Lifesciences's Earnings
See More Headlines
Receive RSLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ReShape Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/13/2020
Today
3/29/2024
Next Earnings (Estimated)
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:RSLS
CUSIP
29365M20
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+4,238.4%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-46,210,000.00
Net Margins
-266.76%
Pretax Margin
-267.11%

Debt

Sales & Book Value

Annual Sales
$11.24 million
Book Value
$7.05 per share

Miscellaneous

Free Float
13,122,000
Market Cap
$2.42 million
Optionable
Not Optionable
Beta
0.19
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives


RSLS Stock Analysis - Frequently Asked Questions

What is ReShape Lifesciences' stock price target for 2024?

0 equities research analysts have issued 12 month price objectives for ReShape Lifesciences' shares. Their RSLS share price targets range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 4,238.4% from the stock's current price.
View analysts price targets for RSLS
or view top-rated stocks among Wall Street analysts.

How have RSLS shares performed in 2024?

ReShape Lifesciences' stock was trading at $0.2497 at the beginning of the year. Since then, RSLS stock has decreased by 26.2% and is now trading at $0.1844.
View the best growth stocks for 2024 here
.

Are investors shorting ReShape Lifesciences?

ReShape Lifesciences saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 428,700 shares, a decrease of 43.3% from the February 29th total of 756,200 shares. Based on an average daily volume of 996,600 shares, the short-interest ratio is currently 0.4 days. Currently, 2.1% of the company's shares are short sold.
View ReShape Lifesciences' Short Interest
.

When is ReShape Lifesciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our RSLS earnings forecast
.

How were ReShape Lifesciences' earnings last quarter?

ReShape Lifesciences Inc. (NASDAQ:RSLS) announced its earnings results on Thursday, August, 13th. The medical device company reported ($8.67) earnings per share for the quarter, beating analysts' consensus estimates of ($218,400.00) by $218,391.33. The medical device company had revenue of $1.70 million for the quarter. ReShape Lifesciences had a negative trailing twelve-month return on equity of 492.62% and a negative net margin of 266.76%.

When did ReShape Lifesciences' stock split?

ReShape Lifesciences shares reverse split on Thursday, December 22nd 2022. The 1-50 reverse split was announced on Thursday, December 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of ReShape Lifesciences?

Shares of RSLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RSLS) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners